These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 12145148

  • 1. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
    Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA.
    Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
    [Abstract] [Full Text] [Related]

  • 2. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH.
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [Abstract] [Full Text] [Related]

  • 6. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
    Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG.
    Eur J Clin Invest; 2002 Jun; 32(6):429-36. PubMed ID: 12059988
    [Abstract] [Full Text] [Related]

  • 7. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L, Parris W, Adeli K, Cheung RC.
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [Abstract] [Full Text] [Related]

  • 8. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 9. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
    Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR.
    Int J Obes Relat Metab Disord; 2003 Jul; 27(7):862-5. PubMed ID: 12821974
    [Abstract] [Full Text] [Related]

  • 10. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
    Chan DC, Watts GF, Nguyen MN, Barrett PH.
    Am J Clin Nutr; 2006 Jul; 84(1):37-43. PubMed ID: 16825679
    [Abstract] [Full Text] [Related]

  • 11. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
    Meyer BJ, Hammervold T, Rustan AC, Howe PR.
    Lipids; 2007 Mar; 42(2):109-15. PubMed ID: 17393216
    [Abstract] [Full Text] [Related]

  • 12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [Abstract] [Full Text] [Related]

  • 14. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
    Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K.
    Metabolism; 2002 Apr; 51(4):409-18. PubMed ID: 11912545
    [Abstract] [Full Text] [Related]

  • 15. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
    Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR.
    Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
    [Abstract] [Full Text] [Related]

  • 16. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 17. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
    Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH.
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
    [Abstract] [Full Text] [Related]

  • 18. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 19. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [Abstract] [Full Text] [Related]

  • 20. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
    Pont F, Duvillard L, Florentin E, Gambert P, Vergès B.
    Arterioscler Thromb Vasc Biol; 2002 Oct 01; 22(10):1726-32. PubMed ID: 12377756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.